Objective: This study aims to develop a practical procedure to assess retired Thoroughbreds for their suitability for equestrian sports or leisure purposes and to assess if horses identified as having reactive temperaments in response to a standardized startle test, will have improved test results following a period of transition training. Methods: Behavioral reactivity data and cardiac autonomic responses to a startle test (comprising of a plastic bag applied to the neck area) were collected from twelve retired Thoroughbred racehorses (6 males and 6 females; average age: 4.33 ± 0.89 years old; average body weight 465.17 ± 25.33 kg), before and after the three-month transition training for equestrian sports. A priori power calculation indicated a requirement of 12 individuals for a power of 80%. Results: Following the training, there was a significant reduction in the behavioral score (BS), peak heart rate (HR), and response duration (RD) of all horses compared to their pre-training scores. However, 25% of horses (3/12) retained a BS of 2 or above post-training, exhibiting significantly higher peak HR and longer RD compared to those with a BS below 2.Post-training, the females demonstrated a significant increase in the root mean square of the successive differences between normal heartbeats compared to their pre-training levels. Conclusions and Relevance: Transition training of retired Thoroughbreds can assist in improving horses' suitability for equestrian sports, based on their successive responses to a novel startle test.

Objective: This study aims to develop a practical procedure to assess retired Thoroughbreds for their suitability for equestrian sports or leisure purposes and to assess if horses identified as having reactive temperaments in response to a standardized startle test, will have improved test results following a period of transition training. Methods: Behavioral reactivity data and cardiac autonomic responses to a startle test (comprising of a plastic bag applied to the neck area) were collected from twelve retired Thoroughbred racehorses (6 males and 6 females; average age: 4.33 ± 0.89 years old; average body weight 465.17 ± 25.33 kg), before and after the three-month transition training for equestrian sports. A priori power calculation indicated a requirement of 12 individuals for a power of 80%. Results: Following the training, there was a significant reduction in the behavioral score (BS), peak heart rate (HR), and response duration (RD) of all horses compared to their pre-training scores. However, 25% of horses (3/12) retained a BS of 2 or above post-training, exhibiting significantly higher peak HR and longer RD compared to those with a BS below 2.Post-training, the females demonstrated a significant increase in the root mean square of the successive differences between normal heartbeats compared to their pre-training levels. Conclusions and Relevance: Transition training of retired Thoroughbreds can assist in improving horses' suitability for equestrian sports, based on their successive responses to a novel startle test.

Objective: This study aims to develop a practical procedure to assess retired Thoroughbreds for their suitability for equestrian sports or leisure purposes and to assess if horses identified as having reactive temperaments in response to a standardized startle test, will have improved test results following a period of transition training. Methods: Behavioral reactivity data and cardiac autonomic responses to a startle test (comprising of a plastic bag applied to the neck area) were collected from twelve retired Thoroughbred racehorses (6 males and 6 females; average age: 4.33 ± 0.89 years old; average body weight 465.17 ± 25.33 kg), before and after the three-month transition training for equestrian sports. A priori power calculation indicated a requirement of 12 individuals for a power of 80%. Results: Following the training, there was a significant reduction in the behavioral score (BS), peak heart rate (HR), and response duration (RD) of all horses compared to their pre-training scores. However, 25% of horses (3/12) retained a BS of 2 or above post-training, exhibiting significantly higher peak HR and longer RD compared to those with a BS below 2.Post-training, the females demonstrated a significant increase in the root mean square of the successive differences between normal heartbeats compared to their pre-training levels. Conclusions and Relevance: Transition training of retired Thoroughbreds can assist in improving horses' suitability for equestrian sports, based on their successive responses to a novel startle test.

Objective: This study aims to develop a practical procedure to assess retired Thoroughbreds for their suitability for equestrian sports or leisure purposes and to assess if horses identified as having reactive temperaments in response to a standardized startle test, will have improved test results following a period of transition training. Methods: Behavioral reactivity data and cardiac autonomic responses to a startle test (comprising of a plastic bag applied to the neck area) were collected from twelve retired Thoroughbred racehorses (6 males and 6 females; average age: 4.33 ± 0.89 years old; average body weight 465.17 ± 25.33 kg), before and after the three-month transition training for equestrian sports. A priori power calculation indicated a requirement of 12 individuals for a power of 80%. Results: Following the training, there was a significant reduction in the behavioral score (BS), peak heart rate (HR), and response duration (RD) of all horses compared to their pre-training scores. However, 25% of horses (3/12) retained a BS of 2 or above post-training, exhibiting significantly higher peak HR and longer RD compared to those with a BS below 2.Post-training, the females demonstrated a significant increase in the root mean square of the successive differences between normal heartbeats compared to their pre-training levels. Conclusions and Relevance: Transition training of retired Thoroughbreds can assist in improving horses' suitability for equestrian sports, based on their successive responses to a novel startle test.

Purpose: This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC). Materials and Methods: Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS). Results: In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib. Conclusion Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.

Background: We evaluated changes in glycemic status, over 1 year, of coronavirus disease 2019 (COVID-19) survivors with dysglycemia in acute COVID-19. Methods: COVID-19 survivors who had dysglycemia (defined by glycosylated hemoglobin [HbA1c] 5.7% to 6.4% or random glucose ≥10.0 mmol/L) in acute COVID-19 were recruited from a major COVID-19 treatment center from September to October 2020. Matched non-COVID controls were recruited from community. The 75-g oral glucose tolerance test (OGTT) were performed at baseline (6 weeks after acute COVID-19) and 1 year after acute COVID-19, with HbA1c, insulin and C-peptide measurements. Progression in glycemic status was defined by progression from normoglycemia to prediabetes/diabetes, or prediabetes to diabetes. Results: Fifty-two COVID-19 survivors were recruited. Compared with non-COVID controls, they had higher C-peptide (P< 0.001) and trend towards higher homeostasis model assessment of insulin resistance (P=0.065). Forty-three COVID-19 survivors attended 1-year reassessment. HbA1c increased from 5.5%±0.3% to 5.7%±0.2% (P<0.001), with increases in glucose on OGTT at fasting (P=0.089), 30-minute (P=0.126), 1-hour (P=0.014), and 2-hour (P=0.165). At baseline, 19 subjects had normoglycemia, 23 had prediabetes, and one had diabetes. Over 1 year, 10 subjects (23.8%; of 42 non-diabetes subjects at baseline) had progression in glycemic status. C-peptide levels remained unchanged (P=0.835). Matsuda index decreased (P=0.007) and there was a trend of body mass index increase from 24.4±2.7 kg/m2 to 25.6±5.2 (P=0.083). Subjects with progression in glycemic status had more severe COVID-19 illness than non-progressors (P=0.030). Reassessment was not performed in the control group. Conclusion Subjects who had dysglycemia in acute COVID-19 were characterized by insulin resistance. Over 1 year, a quarter had progression in glycemic status, especially those with more severe COVID-19. Importantly, there was no significant deterioration in insulin secretory capacity.

Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has beneficial effects on acid-related disorders such as gastroesophageal reflux and peptic ulcer diseases.This study aimed to validate the effect of tegoprazan on endoscopic submucosal dissection (ESD)-induced artificial ulcers. Methods: Patients from 16 centers in Korea who underwent ESD for gastric neoplasia were enrolled. After ESD, pantoprazole was administered intravenously for 48 hours. The patients were randomly allocated to either the tegoprazan or esomeprazole group. Tegoprazan 50 mg or esomeprazole 40 mg were administered for 4 weeks, after which gastroscopic evaluation was performed. If the artificial ulcer had not healed, the same dose of tegoprazan or esomeprazole was administered for an additional 4 weeks, and a gastroscopic evaluation was performed. Results: One hundred sixty patients were enrolled in this study. The healing rates of artificial ulcers at 4 weeks were 30.3% (23/76) and 22.1% (15/68) in the tegoprazan and esomeprazole groups, respectively (p=0.006). At 8 weeks after ESD, the cumulative ulcer healing rates were 73.7% (56/76) and 77.9% (53/68) in the tegoprazan and esomeprazole groups, respectively (p=0.210). Delayed bleeding occurred in two patients in the tegoprazan group (2.6%) and in one patient in the esomeprazole group (1.5%). Other adverse events were negligible in both groups. Conclusions Tegoprazan showed similar effects on post-ESD artificial ulcer healing in comparison with esomeprazole.

Unruptured dural arteriovenous fistula (dAVF) manifests various symptoms including exophthalmos, headache, tinnitus, and retro-orbital pain. Transient global amnesia (TGA) is a clinical syndrome of reversible anterograde amnesia. Here, we report a 62-year-old woman with dAVF, manifested as TGA. This case emphasized that the clinicians should stay vigilance to the organic cause of TGA, especially in those complaining other symptoms besides amnesia such as pulsatile tinnitus and headache. Furthermore, our case supports a hypothetical patho-mechanism of venous congestion for TGA.

Background: Current international guidelines recommend against deep sedation as it is associated with worse outcomes in the intensive care unit (ICU). However, in Korea the prevalence of deep sedation and its impact on patients in the ICU are not well known. Methods: From April 2020 to July 2021, a multicenter, prospective, longitudinal, noninterventional cohort study was performed in 20 Korean ICUs. Sedation depth extent was divided into light and deep using a mean Richmond Agitation–Sedation Scale value within the first 48 hours. Propensity score matching was used to balance covariables; the outcomes were compared between the two groups. Results: Overall, 631 patients (418 [66.2%] and 213 [33.8%] in the deep and light sedation groups, respectively) were included. Mortality rates were 14.1% and 8.4% in the deep and light sedation groups (P = 0.039), respectively. Kaplan-Meier estimates showed that time to extubation (P < 0.001), ICU length of stay (P = 0.005), and death P = 0.041) differed between the groups. After adjusting for confounders, early deep sedation was only associated with delayed time to extubation (hazard ratio [HR], 0.66; 95% confidence inter val [CI], 0.55– 0.80; P < 0.001). In the matched cohort, deep sedation remained significantly associated with delayed time to extubation (HR, 0.68; 95% 0.56–0.83; P < 0.001) but was not associated with ICU length of stay (HR, 0.94; 95% CI, 0.79–1.13; P = 0.500) and in-hospital mortality (HR, 1.19; 95% CI, 0.65–2.17; P = 0.582). Conclusion In many Korean ICUs, early deep sedation was highly prevalent in mechanically ventilated patients and was associated with delayed extubation, but not prolonged ICU stay or in-hospital death.

Background: Insulin-treated patients with long duration of type 2 diabetes mellitus (T2DM) are at increased risk of ketoacidosis related to sodium-glucose co-transporter 2 inhibitor (SGLT2i). The extent of circulating ketone elevation in these patients remains unknown. We conducted this study to compare the serum ketone response between dapagliflozin, an SGLT2i, and sitagliptin, a dipeptidyl peptidase-4 inhibitor, among insulin-treated T2DM patients. Methods: This was a randomized, open-label, active comparator-controlled study involving 60 insulin-treated T2DM patients. Participants were randomized 1:1 for 24-week of dapagliflozin 10 mg daily or sitagliptin 100 mg daily. Serum β-hydroxybutyrate (BHB) levels were measured at baseline, 12 and 24 weeks after intervention. Comprehensive cardiometabolic assessments were performed with measurements of high-density lipoprotein cholesterol (HDL-C) cholesterol efflux capacity (CEC), vibration-controlled transient elastography and echocardiography. Results: Among these 60 insulin-treated participants (mean age 58.8 years, diabetes duration 18.2 years, glycosylated hemoglobin 8.87%), as compared with sitagliptin, serum BHB levels increased significantly after 24 weeks of dapagliflozin (P=0.045), with a median of 27% increase from baseline. Change in serum BHB levels correlated significantly with change in free fatty acid levels. Despite similar glucose lowering, dapagliflozin led to significant improvements in body weight (P=0.006), waist circumference (P=0.028), HDL-C (P=0.041), CEC (P=0.045), controlled attenuation parameter (P=0.007), and liver stiffness (P=0.022). Average E/e’, an echocardiographic index of left ventricular diastolic dysfunction, was also significantly lower at 24 weeks in participants treated with dapagliflozin (P=0.037). Conclusion Among insulin-treated T2DM patients with long diabetes duration, compared to sitagliptin, dapagliflozin modestly increased ketone levels and was associated with cardiometabolic benefits.